Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IntReALL HR 2010 bortezomib trial in high-risk relapsed childhood ALL
NL-OMON49335Phase 2Recruiting
- Sponsor
- Charité – Universitätsmedizin Berlin
- Start
- Oct 2020
- Modality
- Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of bortezomib in acute lymphoblastic leukemia (ALL), sponsored by Charité – Universitätsmedizin Berlin. Started Oct 2020; status: recruiting.
02
Drugs
bortezomib
03
Conditions
acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on NL-OMON49335.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON49335.